ftInvstr
INNOVACAP · Healthcare ₹1178.9 +3.96% Mkt Cap ₹6734 Cr overvalued

INNOVACAP

Healthcare Drug Manufacturers - Specialty & Generic
₹1178.9
+3.96% today · 30d +24.07%
as of 2026-09-04
Price · Daily Candles
“INNOVACAP's Growth Momentum Continues with FIIs on the Rise, Despite Softening FCF Projections”
Innovacap demonstrates strong revenue growth, with Q4 sales up 42.28% YoY to ₹448 Cr and annual revenue rising 31.06% to ₹1630 Cr. Net profit also surged 28.78% QoQ to ₹38 Cr. However, ML predictions forecast a significant compression in Free Cash Flow (FCF), despite current FCF yield sitting at 1.0%.
BULL CASE
+Q4 revenue registered a strong 42.28% YoY increase, reaching ₹448 Cr.
+Annual revenue for FY26 grew by 31.06% YoY to ₹1630 Cr, indicating sustained top-line expansion.
+Net profit in Q4 rose by 28.78% QoQ to ₹38 Cr, reflecting improved profitability.
+FII shareholding increased by 0.12 percentage points QoQ to 0.23% as of March 2026.
+The 5-year Net Profit CAGR stands at 32.52%, showcasing consistent historical earnings growth.
BEAR CASE
The ML model predicts severe Free Cash Flow compression, with H1 FCF projected to decrease by 50.0% and H2 by 50.0% of market cap.
Operating Profit Margin for Q4 saw a -1.22 percentage point change YoY, despite overall profit growth.
The stock is trading 17.21% below its 52-week high of ₹1020.7.
DII shareholding declined by 0.10 percentage points QoQ to 20.14% as of March 2026.
While PE TTM is 34.25, the ROE (not explicitly provided but deduced from other ratios implicitly) would need to justify this higher valuation when compared to FCF compression.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹471 Cr
+33.94% YoY
NET PROFIT
₹44 Cr
+42.27% YoY
OPM
15.89%
-0.01pp YoY
EPS
₹7.71
PE 34.25
Intrinsic value · DCF ₹127.35 · Margin of safety -89.2% (overvalued) · FCF yield 0.72%
◇ Sector Position
INNOVACAP's PE of 34.25 and ROCE of 15.0% position it below industry leaders like SUNPHARMA (PE 40.41, ROCE 22.46%) and DIVISLAB (PE 69.81, ROCE 21.47%), suggesting a relatively lower valuation and efficiency within the Drug Manufacturers - Specialty & Generic sector.
PEERPEROCE %
INNOVACAP34.2515.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
70
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 90
Valuation FAIR 40
Growth STEADY 67
Profitability HIGH 78
Technicals NEUTRAL 68
Risk LOW 80
Key Stats
TTM PE
34.25
P/B
4.73
52W HIGH
₹1199.9
OFF HIGH
-1.75%
DIV YIELD
0.47%
MKT CAP
₹6734 Cr
◉ Active Signals
MACDBullish10.0652
RSI(14)Bearish72.91
Near 52W HighBullish-1.75
Street Consensus
2 analysts
₹1078.5
mean target
Low ₹1025.0Now ₹1178.9High ₹1132.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold INNOVACAP and at what entry.

Sign up freeSign in